Bellerophon Therapeutics, Inc.
BLPH · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | 0.04 | -0.28 | 0.00 |
| FCF Yield | -206.73% | -77.47% | -38.23% | -54.71% |
| EV / EBITDA | -0.08 | -0.29 | -0.23 | -1.09 |
| Quality | ||||
| ROIC | -728.98% | -81.09% | -59.73% | -224.92% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.90 | 1.29 | 0.80 | 0.98 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 22.13% | -14.77% | -53.71% | 16.52% |
| Safety | ||||
| Net Debt / EBITDA | 0.30 | 1.22 | 1.72 | 0.51 |
| Interest Coverage | -165.81 | -4,032.20 | -105.10 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -6,906.92 | -4,265.49 | -9,249.15 | -3,257.73 |